<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066400</url>
  </required_header>
  <id_info>
    <org_study_id>2018-13078</org_study_id>
    <nct_id>NCT04066400</nct_id>
  </id_info>
  <brief_title>Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis</brief_title>
  <acronym>NASH-ATI</acronym>
  <official_title>Role of a Wheat-based Diet in NASH (NASH-ATI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of Wheat-based diet vs. ATI-free diet on NASH
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 patients with the diagnosis of a non-alcoholic- steatohepatitis (NASH) will be recruited
      at the University Hospitals of Mainz and Frankfurt. Patients are assessed with regards to
      their diet using standardized questionnaire and nutritionists.

      Patients will be randomized into two parallel groups. The first group will continue a
      wheat-based Nutrition, while the second Group will receive dietary counselling to achieve an
      ATI-free nutrition, trying to reduce the daily ATI consumption.

      The clinical trial will run over 16 weeks including 4 visits at the study center. Study
      visits include physical examinations, blood-based parameters, cytokines and urine samples, as
      well for the analysis of the intestinal microbiome by using stool samples. In addition the
      patients have to complete dietary and health-related quality of life (HRQL) questionnaires.
      Visits are planned at baseline, W4, W8 and W16.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective, randomized, controlled, bicentric pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of ATI-free Nutrition on hepatic inflammation</measure>
    <time_frame>16 weeks</time_frame>
    <description>Reduction of Alanine-Aminotransferase (ALT; U/ml) compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using the chronic liver disease questionnaire (CLDQ)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The CLDQ is a validated patient-reported outcome measure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>wheat-based diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients continue a wheat-based diet aiming at a reduction in bodyweight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATI reduced diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are counselled to reduce dietary gluten uptake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nutritional Intervention</intervention_name>
    <description>Dietary Counselling</description>
    <arm_group_label>ATI reduced diet</arm_group_label>
    <arm_group_label>wheat-based diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven NASH in the past 36 months with increased ALT: males: &gt;60,
             females: &gt;42 U/ml

          -  no body weight modification about &gt;10% in the past 24 weeks

          -  no new drugs treating parts of the metabolic syndrome in the past 12 weeks

          -  for patients with Diabetes: HbA1c value &lt;8,6%

          -  the ability to understand the aim and the possible individual consequences of this
             Trial

          -  signed and dated consent before the Trial starts

        Exclusion Criteria:

          -  unstable coronary heart disease, stroke in the past 6 months

          -  different liver diseases

          -  proceeded fibrosis (Fibroscan &gt;9,6 kPA) or histological cirrhosis

          -  hepatocellular carcinoma or not curative treated carcinomas

          -  alcohol consumption &gt;10g/day (females), &gt;20g/day (males)

          -  gravidity

          -  drugs causing secondary NASH (e.g. Tamoxifen, corticosteroids)

          -  immunological or inflammatory diseases (e.g. systemic Lupus erythematodes)

          -  warfarin therapy

          -  implementation of another Special diet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jörn M Schattenbrg, MD</last_name>
    <phone>00496131176074</phone>
    <email>joern.schattenberg@unimedizin-mainz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Detlef Schuppan, MD PhD</last_name>
    <email>detlef.schuppan@unimedizin-mainz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörn Schattenberg, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 17, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Priv.-Doz. Dr. J. Schattenberg</investigator_full_name>
    <investigator_title>Director Metabolic Liver Disease Program</investigator_title>
  </responsible_party>
  <keyword>hepatic inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

